Evidence map›Paper›PMID 38822136›Full record

ArticlePediatric research2025

Eltrombopag combined with immunosuppressive therapy for pediatric severe aplastic anemia.

Bixi Yang, Lingling Fu, Hongmin Li, Hui Chen, Rui Zhang, Jiafeng Yao, Liqiang Zhang, Runhui Wu, Jie Ma

Abstract read
PubMed Publisher
In one paragraph

Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Bixi YangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Lingling FuDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Hongmin LiDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Hui ChenHematologic Disease Laboratory, Hematology Center, Beijing, China.
Rui ZhangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jiafeng YaoDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Liqiang ZhangDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Runhui WuDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
Jie MaDepartment of Hematology, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. 15188805@qq.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSevere aplastic anemia (SAA) is caused by immune-mediated destruction. Standard immunosuppressive therapy (IST) is effective but needs to be improved.

methodsThe data of patients with SAA and received IST were analyzed retrospectively to conducted this historical control study.

resultsA total of 115 SAA patients (60 males; median age of 5.77 years and median follow-up time of 45 months) were enrolled in this study. The complete response rates (CRR) of the eltrombopag group at 3 and 6 months were higher than the control group (30.3% vs.8.2% at 3 months; 50.0% vs. 10.2% at 6 months). The overall response rates (ORR) showed no differences. There were significant differences in the times from G-CSF, Red blood cell transfusion, and Platelet transfusion between the two groups. No difference in overall survival (OS), event-free survival (EFS), and relapse rate between two groups. There is no variable were associated with prognosis in both groups.

conclusionAddition of eltrombopag to IST confers faster hematological response and higher early hematological response in pediatric SAA patients. IMPACT: Addition of eltrombopag to standard immunosuppressive therapy confers faster hematological response and higher early hematological response in pediatric severe aplastic anemia patients. Eltrombopag showed reliable safety but had no impact on long-term response and prognosis. This article is a historical controlled study consisting of 115 pediatric severe aplastic anemia patients and makes up for the lack of clinical data deficient on pediatric severe aplastic anemia with TPO-RA combined with IST.

Indexed as

Anemia, AplasticBenzoatesHydrazinesImmunosuppression TherapyImmunosuppressive AgentsPyrazolesAdolescentChildChild, PreschoolDisease-Free SurvivalDrug Therapy, CombinationFemaleHumansInfantMaleRetrospective StudiesBenzoateseltrombopagHydrazinesImmunosuppressive AgentsPyrazoles

Identifiers

PMID38822136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.